Irofulven CAS 920014-72-8 Setmelanotide
TDS 4 Inquiries
920014-72-8
Pharmaceutical Grade
99%
/
HORLDEN
1g
2026-01-30
Chemical,Intermediate,5-amino-1mq,SLU-PP332,Tirzepatide,Peptide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Setmelanotide is a synthetic peptide and selective melanocortin-4 receptor (MC4R) agonist. As a peptide-based pharmaceutical raw material, Setmelanotide is characterized by its defined molecular structure and receptor activity. It is suitable for API research, analytical testing, pharmaceutical development, and related manufacturing processes.
Certificates-
TDS
Basic Info-
Product Name:
Setmelanotide
Other Name:Setmelanotide;920014-72-8;UNII-N7T15V1FUY;BIM-22493;RM-493;Imcivree;N7T15V1FUY;(4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide;Setmelanotide [USAN:INN];GTPL9272
CAS No.:920014-72-8
Molecular Formula:C49H68N18O9S2
InChIKeys:HDHDTKMUACZDAA-PHNIDTBTSA-N
Molecular Weight:1117.31
Exact Mass:1116.49
UNII:N7T15V1FUY
ATC Code:A08AA
Categories:
Characteristics-
PSA:
494.76
XLogP3:3.0807
Research-
Class:
MC4R (melanocortin-4 receptor) agonist (8-amino-acid cyclic peptide)
Status:FDA-approved (Imcivree 2020) — orphan drug for genetic obesity
Mechanism:A first-in-class, 8-amino-acid cyclic peptide (Ac-Arg-cyclo[Cys-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2) that acts as a selective MC4R agonist. MC4R is a key regulator of hunger, satiety, and energy expenditure in the hypothalamus. Setmelanotide restores melanocortin signaling in patients with genetic defects in the leptin-melanocortin pathway, producing significant weight loss without cardiovascular side effects.
EC50 (Human Mc4r Ki):2.1 nM
EC50 (Human Mc4r Ec50):0.27 nM
Source:DrugBank: DB11700; ChemicalBook: CAS 920014-72-8; target validation: Chen C, et al.
Clinical Development:FDA:Imcivree (approved 2020-11-25)
References-
DrugBank:PubChem:Literature:
FDA: Imcivree (NDA 213793); NEJM: Clément K, et al. (2020) — Setmelanotide for POMC deficiency
Disclaimer:Setmelanotide is FDA-approved as a prescription medicine (Imcivree) for rare genetic forms of obesity (POMC/LEPR deficiency, Bardet-Biedl syndrome, Alström syndrome). This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Chemical,Intermediate,5-amino-1mq,SLU-PP332,Tirzepatide,Peptide
-
Location:
9th Floor, Room 923, Building 3, Shiyuan Daguan, Xingtai 1st Street, Chanba Ecological District, Xi'an City, Shaanxi Province
-
Payment Terms:
100% TT in advance
-
Average lead Time:
7
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
11-50
-
Year of Establishment:
2015
-
-
Inquiry History4 Inquiries
Country Product Purchase Quantity Date Posted 
Singapore
Setmelanotide
1 G Aug 8, 2026 
United Kingdom
Setmelanotide
1 G Dec 17, 2024
United Kingdom
Setmelanotide
1 G Dec 17, 2024 
United States
Setmelanotide
2 G May 20, 2024 Post an enquiry for this product
